7,455 Shares in Guardant Health, Inc. $GH Purchased by Ieq Capital LLC

Ieq Capital LLC purchased a new stake in Guardant Health, Inc. (NASDAQ:GH) during the second quarter, HoldingsChannel.com reports. The firm purchased 7,455 shares of the company’s stock, valued at approximately $1,118,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Elyxium Wealth LLC acquired a new stake in Guardant Health during the fourth quarter worth approximately $35,000. Parallel Advisors LLC boosted its holdings in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares during the period. Ascentis Independent Advisors acquired a new position in shares of Guardant Health in the first quarter valued at approximately $38,000. Hollencrest Capital Management bought a new position in shares of Guardant Health during the first quarter worth approximately $41,000. Finally, EFG International AG acquired a new stake in Guardant Health during the 4th quarter worth approximately $41,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on GH shares. TD Cowen restated a “buy” rating on shares of Guardant Health in a research note on Tuesday. Mizuho increased their price objective on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. Canaccord Genuity Group lifted their target price on Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Sanford C. Bernstein boosted their target price on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, July 2nd. Finally, Citigroup upped their price target on shares of Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $183.78.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $170.92 on Thursday. The business’s 50 day simple moving average is $156.17 and its 200 day simple moving average is $120.00. Guardant Health, Inc. has a 1 year low of $53.40 and a 1 year high of $176.58. The company has a market capitalization of $22.94 billion, a P/E ratio of -48.97 and a beta of 1.60.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. Guardant Health’s revenue was up 44.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.44) earnings per share. On average, sell-side analysts anticipate that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Insider Buying and Selling

In other Guardant Health news, Director Ian T. Clark sold 14,180 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the sale, the director directly owned 2,975 shares in the company, valued at $472,787. This represents a 82.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Terilyn J. Monroe sold 46,300 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the sale, the insider owned 22,979 shares in the company, valued at $3,794,292.48. The trade was a 66.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 548,318 shares of company stock valued at $82,501,873 in the last ninety days. Insiders own 5.60% of the company’s stock.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.